TOT-HER3
Window Program
A window-of-opportunity study of U3-1402, a HER3-targeting antibody-drug conjugate in operable breast cancer according to ERBB3 expression
Phase 0
Status
Recruiting
Tumour subtype:
HR+
Scenario
Neoadjuvant
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Aleix Prat, MD, PhD (Hospital Clínic de Barcelona)
Mafalda Oliveira, MD, PhD (Hospital Vall d'Hebron de Barcelona)
Sites
HOSPITAL CLINIC DE BARCELONA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL DE FUENLABRADA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DE CANARIAS, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, ICO BADALONA, ICO HOSPITALET (DURAN I REYNALS)
